Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT ID: NCT01210222
Last Updated: 2018-02-23
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
35 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-06-06
Study Completion Date
2016-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Endometrial Cancer
RECRUITING
PHASE1/PHASE2
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887
Endometrial Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Mucinous Adenocarcinoma
+6 more
COMPLETED
PHASE2
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01132820
Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
+2 more
COMPLETED
PHASE2
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
NCT02101788
Borderline Ovarian Serous Tumor
Micropapillary Serous Carcinoma
Ovarian Serous Adenocarcinoma
+3 more
COMPLETED
PHASE2/PHASE3
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
NCT00379145
Sarcoma
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To estimate the proportion of patients with persistent or recurrent endometrial cancer, who survive progression-free for at least 6 months and the proportion of patients who have objective tumor response (complete or partial), treated with AMG 386 (trebananib).
II. To determine the nature and degree of toxicity of AMG 386 in this cohort of patients.
SECONDARY OBJECTIVES:
I. To estimate the progression-free survival (PFS) and overall survival (OS) of patients with persistent or recurrent endometrial cancer treated with AMG 386.
OUTLINE:
Patients receive trebananib intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
I. To estimate the proportion of patients with persistent or recurrent endometrial cancer, who survive progression-free for at least 6 months and the proportion of patients who have objective tumor response (complete or partial), treated with AMG 386 (trebananib).
II. To determine the nature and degree of toxicity of AMG 386 in this cohort of patients.
SECONDARY OBJECTIVES:
I. To estimate the progression-free survival (PFS) and overall survival (OS) of patients with persistent or recurrent endometrial cancer treated with AMG 386.
OUTLINE:
Patients receive trebananib intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Endometrial Serous Adenocarcinoma
Endometrioid Stromal Sarcoma
Recurrent Uterine Corpus Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (trebananib)
Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Trebananib
Intervention Type
BIOLOGICAL
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trebananib
Given IV
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments; histologic confirmation of the original primary tumor is required; stained slides to document the primary tumor as well as recurrent/persistent disease (if documented by histology or cytology) are required
* Patients with the following histologic epithelial cell types are eligible:
* Endometrioid adenocarcinoma
* Serous adenocarcinoma
* Undifferentiated carcinoma
* Clear cell adenocarcinoma
* Mixed epithelial carcinoma
* Adenocarcinoma not otherwise specified (N.O.S.)
* Mucinous adenocarcinoma
* Squamous cell carcinoma
* Transitional cell carcinoma
* All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be \>= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \>= 20 mm when measured by chest x-ray; lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI
* Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as 'non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence \>= 90 days following completion of radiation therapy
* Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG phase III or Rare Tumor protocol for the same patient population
* Patients who have received one prior chemotherapy regimen must have a GOG performance status of 0, 1, or 2; patients who have received two prior chemotherapy regimens must have a GOG performance status of 0 or 1
* Recovery from effects of recent surgery, radiotherapy, or chemotherapy
* Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection \[UTI\])
* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
* Any other prior therapy directed at the malignant tumor, including chemotherapy and immunologic agents, must be discontinued at least three weeks prior to registration
* Any prior radiation therapy must be completed at least 4 weeks prior to registration
* Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a chemotherapy regimen
* Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent disease
* Patients must have NOT received any non-cytotoxic (biologic or targeted) agents as part of their primary treatment or for management of recurrent or persistent disease
* Non-cytotoxic (biologic or targeted) agents include (but are not limited to) monoclonal antibodies, cytokines, and small-molecule inhibitors of signal transduction
* Prior hormonal therapy is allowed; there is no limit on the number of prior hormonal therapies allowed
* Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
* Platelets greater than or equal to 100,000/mcl
* Hemoglobin level \>= 9.0 g/dL
* Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) or a creatinine clearance \>= 60 ml/m\^2
* Bilirubin less than or equal to 1.5 x ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
* Alkaline phosphatase less than or equal to 2.5 x ULN
* Neuropathy (sensory and motor) less than or equal to grade 1
* Prothrombin time (PT) such that international normalized ratio (INR) is =\< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =\< 1.5 x ULN
* Albumin \>= 2.8 mg/dL
* Patients must have a urine protein of =\< 1 on dipstick; if dipstick is 2+ or higher, 24-hour urine protein must be obtained and should be \< 1 g for patient to be eligible
* Patients must have signed an approved informed consent and authorization permitting release of personal health information
* Patients of child bearing potential must agree to use an accepted and effective non-hormonal method of contraception i.e., double barrier method (e.g. condom plus diaphragm) from the time of signing the informed consent through 6 months after last dose of study drug
* Patients with the following histologic epithelial cell types are eligible:
* Endometrioid adenocarcinoma
* Serous adenocarcinoma
* Undifferentiated carcinoma
* Clear cell adenocarcinoma
* Mixed epithelial carcinoma
* Adenocarcinoma not otherwise specified (N.O.S.)
* Mucinous adenocarcinoma
* Squamous cell carcinoma
* Transitional cell carcinoma
* All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be \>= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \>= 20 mm when measured by chest x-ray; lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI
* Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as 'non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence \>= 90 days following completion of radiation therapy
* Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG phase III or Rare Tumor protocol for the same patient population
* Patients who have received one prior chemotherapy regimen must have a GOG performance status of 0, 1, or 2; patients who have received two prior chemotherapy regimens must have a GOG performance status of 0 or 1
* Recovery from effects of recent surgery, radiotherapy, or chemotherapy
* Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection \[UTI\])
* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
* Any other prior therapy directed at the malignant tumor, including chemotherapy and immunologic agents, must be discontinued at least three weeks prior to registration
* Any prior radiation therapy must be completed at least 4 weeks prior to registration
* Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a chemotherapy regimen
* Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent disease
* Patients must have NOT received any non-cytotoxic (biologic or targeted) agents as part of their primary treatment or for management of recurrent or persistent disease
* Non-cytotoxic (biologic or targeted) agents include (but are not limited to) monoclonal antibodies, cytokines, and small-molecule inhibitors of signal transduction
* Prior hormonal therapy is allowed; there is no limit on the number of prior hormonal therapies allowed
* Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
* Platelets greater than or equal to 100,000/mcl
* Hemoglobin level \>= 9.0 g/dL
* Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) or a creatinine clearance \>= 60 ml/m\^2
* Bilirubin less than or equal to 1.5 x ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
* Alkaline phosphatase less than or equal to 2.5 x ULN
* Neuropathy (sensory and motor) less than or equal to grade 1
* Prothrombin time (PT) such that international normalized ratio (INR) is =\< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =\< 1.5 x ULN
* Albumin \>= 2.8 mg/dL
* Patients must have a urine protein of =\< 1 on dipstick; if dipstick is 2+ or higher, 24-hour urine protein must be obtained and should be \< 1 g for patient to be eligible
* Patients must have signed an approved informed consent and authorization permitting release of personal health information
* Patients of child bearing potential must agree to use an accepted and effective non-hormonal method of contraception i.e., double barrier method (e.g. condom plus diaphragm) from the time of signing the informed consent through 6 months after last dose of study drug
Exclusion Criteria
* Patients who are currently or have been previously treated with trebananib, or other molecules that inhibit the angiopoietins or Tie2 receptor
* Patient with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
* Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
* Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
* Patients who are pregnant or nursing
* Patients with symptoms of partial or complete bowel obstruction; recent (within 6 months) history of fistula, intraabdominal abscess or bowel perforation; subjects requiring total parenteral nutrition or parenteral hydration
* Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including brain tumor, seizures not controlled with standard medical therapy or any brain metastases
* Patients with clinically significant cardiovascular disease; this includes:
* Myocardial infarction or unstable angina within 12 months of the first date of study treatment
* New York Heart Association (NYHA) Class II or greater congestive heart failure
* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
* Grade 2 or greater peripheral vascular disease
* Cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study treatment
* History of arterial ischemia or thrombus
* Patients with uncontrolled hypertension defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg; the use of anti-hypertensive medications to control hypertension is permitted
* Patients with significant bleeding within 6 months of enrollment or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
* Patients who have undergone major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of study treatment or who have major surgical procedure anticipated during the course of the study
* Patients who have undergone minor surgical procedures within 7 days of the first date of study treatment
* Paracentesis and thoracentesis are permitted prior to and while on study at the discretion of the investigator and as clinically indicated
* Patients treated with immune modulators such as systemic cyclosporine or tacrolimus within 30 days prior to enrollment
* Patients with serious non-healing wound, ulcer (including gastrointestinal), or bone fracture
* Patients with known human immunodeficiency virus (HIV), hepatitis C or chronic or active hepatitis B
* Patients with any condition which, in the investigator's opinion, makes the patient unsuitable for study participation
* Patients not available for follow-up assessments
* Patients with known sensitivity to any of the products to be administered during dosing
* Patients with history of allergic reactions to bacterially produced proteins
* Patients with a history of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
* Patient with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
* Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
* Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
* Patients who are pregnant or nursing
* Patients with symptoms of partial or complete bowel obstruction; recent (within 6 months) history of fistula, intraabdominal abscess or bowel perforation; subjects requiring total parenteral nutrition or parenteral hydration
* Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including brain tumor, seizures not controlled with standard medical therapy or any brain metastases
* Patients with clinically significant cardiovascular disease; this includes:
* Myocardial infarction or unstable angina within 12 months of the first date of study treatment
* New York Heart Association (NYHA) Class II or greater congestive heart failure
* History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
* Grade 2 or greater peripheral vascular disease
* Cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study treatment
* History of arterial ischemia or thrombus
* Patients with uncontrolled hypertension defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg; the use of anti-hypertensive medications to control hypertension is permitted
* Patients with significant bleeding within 6 months of enrollment or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
* Patients who have undergone major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of study treatment or who have major surgical procedure anticipated during the course of the study
* Patients who have undergone minor surgical procedures within 7 days of the first date of study treatment
* Paracentesis and thoracentesis are permitted prior to and while on study at the discretion of the investigator and as clinically indicated
* Patients treated with immune modulators such as systemic cyclosporine or tacrolimus within 30 days prior to enrollment
* Patients with serious non-healing wound, ulcer (including gastrointestinal), or bone fracture
* Patients with known human immunodeficiency virus (HIV), hepatitis C or chronic or active hepatitis B
* Patients with any condition which, in the investigator's opinion, makes the patient unsuitable for study participation
* Patients not available for follow-up assessments
* Patients with known sensitivity to any of the products to be administered during dosing
* Patients with history of allergic reactions to bacterially produced proteins
* Patients with a history of venous or arterial thromboembolism within 12 months prior to enrollment/randomization
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Gynecologic Oncology Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathleen Moore
Role: PRINCIPAL_INVESTIGATOR
NRG Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hartford Hospital
Hartford, Connecticut, United States
Site Status
The Hospital of Central Connecticut
New Britain, Connecticut, United States
Site Status
Sarasota Memorial Hospital
Sarasota, Florida, United States
Site Status
Memorial University Medical Center
Savannah, Georgia, United States
Site Status
Rush University Medical Center
Chicago, Illinois, United States
Site Status
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site Status
Sudarshan K Sharma MD Limted-Gynecologic Oncology
Hinsdale, Illinois, United States
Site Status
Memorial Medical Center
Springfield, Illinois, United States
Site Status
Saint Vincent Hospital and Health Care Center
Indianapolis, Indiana, United States
Site Status
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, United States
Site Status
Iowa Methodist Medical Center
Des Moines, Iowa, United States
Site Status
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, United States
Site Status
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, United States
Site Status
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, United States
Site Status
Mercy Medical Center - Des Moines
Des Moines, Iowa, United States
Site Status
Iowa Lutheran Hospital
Des Moines, Iowa, United States
Site Status
Maine Medical Center-Bramhall Campus
Portland, Maine, United States
Site Status
University of Mississippi Medical Center
Jackson, Mississippi, United States
Site Status
CoxHealth South Hospital
Springfield, Missouri, United States
Site Status
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Site Status
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, United States
Site Status
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
Winston-Salem, North Carolina, United States
Site Status
MetroHealth Medical Center
Cleveland, Ohio, United States
Site Status
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Site Status
Riverside Methodist Hospital
Columbus, Ohio, United States
Site Status
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Site Status
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, United States
Site Status
Abington Memorial Hospital
Abington, Pennsylvania, United States
Site Status
Women and Infants Hospital
Providence, Rhode Island, United States
Site Status
AnMed Health Cancer Center
Anderson, South Carolina, United States
Site Status
Saint Francis Hospital
Greenville, South Carolina, United States
Site Status
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
Site Status
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-02655
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000686066
Identifier Type: -
Identifier Source: secondary_id
GOG-0229L
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-0229L
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-0229L
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
NCT03015129
COMPLETED
PHASE2
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT05691010
RECRUITING
EARLY_PHASE1
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005840
COMPLETED
PHASE1
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826
ACTIVE_NOT_RECRUITING
PHASE2
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer
NCT01041027
TERMINATED
PHASE2
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
NCT00003821
WITHDRAWN
PHASE2
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005830
COMPLETED
PHASE1
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
NCT00377520
COMPLETED
PHASE2
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00574951
TERMINATED
PHASE2
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01074411
COMPLETED
PHASE1
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728258
COMPLETED
PHASE2
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
NCT04395079
ACTIVE_NOT_RECRUITING
PHASE2
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
NCT00003127
COMPLETED
PHASE2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT01935934
COMPLETED
PHASE2
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00006011
COMPLETED
PHASE3
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
NCT01307631
COMPLETED
PHASE2
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935973
COMPLETED
PHASE1
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00087100
COMPLETED
PHASE2
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
NCT03077698
TERMINATED
PHASE2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831
RECRUITING
PHASE2/PHASE3
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489
COMPLETED
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00462826
COMPLETED
PHASE2
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00095979
COMPLETED
PHASE2
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
NCT00002493
COMPLETED
PHASE3